SlidesetHIVRio de Janeiro HIV Clinical Forum 2018Clinical case presentation | Marcio de Figueiredo Fernandes, MDView Slideset
SlidesetHIVMexican HIV Clinical Forum 2018Pharmacological Characteristics and Delivery Options of the Integrase Inhibitors | Courtney Fletcher, PharmDView Slideset
SlidesetHIVMexican HIV Clinical Forum 2018Clinical case presentation | Santiago Pérez Patrigeon, PhDView Slideset
SlidesetHIVMexican HIV Clinical Forum 2018HIV integrase Inhibitors: A novel mechanisms of action | Francisco Flores Murrieta, PhDView Slideset
SlidesetHIVMexican HIV Clinical Forum 2018Integrase Inhibitors in Women and Pediatrics | Alberto Chaparro-Sánchez, MDView Slideset
SlidesetHIVMexican HIV Clinical Forum 2018Optimal use of Integrase Inhibitors in Routine Patient Care in Mexico | Luis Soto-Ramirez, MDView Slideset
SlidesetHIVMexican HIV Clinical Forum 2018Clinical case presentation | Samuel Navarro, MDView Slideset
MSMauro SchechterMD, PhDSlidesetHIVMexican HIV Clinical Forum 2018Clinical case presentation | Mauro Schechter, MD, PhDView Slideset
PTPablo TebasMDSlidesetHIVMexican HIV Clinical Forum 2018Clinical Update on Integrase Inhibitors: Recent Data | Pablo Tebas, MDView Slideset
SlidesetHIVArgentina HIV Clinical Forum 2018Pharmacology and new modes of delivery | David Back, PhDView Slideset
SlidesetHIVArgentina HIV Clinical Forum 2018HIV Integrase Inhibitors: A new mechanism of action | Charles Boucher, MD, PhDView Slideset
